Scynexis (SCYX) Cash from Investing Activities (2013 - 2026)
Scynexis' (SCYX) quarterly Cash from Investing Activities came in at -$24.8 million in Q2 2026, down 319.62% on a YoY basis from $11.3 million in Q2 2025, and down 4615.81% quarter-over-quarter from -$525000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Cash from Investing Activities for 14 consecutive years, with -$24.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Investing Activities fell 319.62% year-over-year to -$24.8 million; the trailing twelve-month figure through Jun 2026 stood at -$24.7 million (down 207.18% YoY), and the FY2025 full-year result was $24.3 million, up 295.22% from the prior year.
- Cash from Investing Activities retreated to -$24.8 million in Q2 2026 per SCYX's latest filing, from -$525000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $12.4 million in Q1 2025 and bottomed at -$27.4 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$3.8 million across 5 years, with a median of -$525000.0 in 2026.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities tumbled 8000.59% in 2022, then soared 721.65% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$27.4 million in 2022, then jumped by 92.14% to -$2.2 million in 2023, then fell by 21.61% to -$2.6 million in 2024, then sank by 351.82% to -$11.8 million in 2025, then sank by 109.39% to -$24.8 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$24.8 million, -$525000.0, and -$11.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 281.26 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -24.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.76 Mn |
| Mar 31, 2026 | -525,000.00 |
| Dec 31, 2025 | -11.82 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 5.45 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Sep 30, 2023 | -26.34 Mn |
| Jun 30, 2023 | -6.38 Mn |
| Sep 30, 2022 | -27.38 Mn |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | -583,000.00 |
| Sep 30, 2021 | -338,000.00 |
| Jun 30, 2021 | -51,000.00 |
| Mar 31, 2021 | -200,000.00 |
| Sep 30, 2020 | 3.57 Mn |